Legal & General Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-32,839
| Closed | -$10.4M | – | 3384 |
|
|
2023
Q4 | $10.4M | Sell |
32,839
-1,833
| -5% | -$356K | ﹤0.01% | 1115 |
|
|
2023
Q3 | $5.86M | Buy |
34,672
+2,478
| +8% | +$466K | ﹤0.01% | 1358 |
|
|
2023
Q2 | $6.98M | Buy |
32,194
+1,154
| +4% | +$247K | ﹤0.01% | 1269 |
|
|
2023
Q1 | $5.64M | Buy |
31,040
+3,224
| +12% | +$617K | ﹤0.01% | 1353 |
|
|
2022
Q4 | $5.47M | Buy |
27,816
+2,775
| +11% | +$595K | ﹤0.01% | 1360 |
|
|
2022
Q3 | $5.63M | Buy |
25,041
+2,359
| +10% | +$477K | ﹤0.01% | 1314 |
|
|
2022
Q2 | $2.87M | Buy |
22,682
+1,854
| +9% | +$213K | ﹤0.01% | 1700 |
|
|
2022
Q1 | $2.64M | Buy |
20,828
+2,388
| +13% | +$269K | ﹤0.01% | 1857 |
|
|
2021
Q4 | $2.42M | Buy |
18,440
+406
| +2% | +$52.5K | ﹤0.01% | 1942 |
|
|
2021
Q3 | $2.21M | Buy |
18,034
+3,993
| +28% | +$461K | ﹤0.01% | 1982 |
|
|
2021
Q2 | $1.6M | Buy |
14,041
+4,626
| +49% | +$541K | ﹤0.01% | 2068 |
|
|
2021
Q1 | $1.13M | Sell |
9,415
-25
| -0.3% | -$2.83K | ﹤0.01% | 2162 |
|
|
2020
Q4 | $959K | Sell |
9,440
-58
| -0.6% | -$5.37K | ﹤0.01% | 2127 |
|
|
2020
Q3 | $734K | Buy |
9,498
+5,311
| +127% | +$453K | ﹤0.01% | 2111 |
|
|
2020
Q2 | $466K | Buy |
4,187
+2,557
| +157% | +$222K | ﹤0.01% | 2187 |
|
|
2020
Q1 | $117K | Buy |
1,630
+757
| +87% | +$64.7K | ﹤0.01% | 2371 |
|
|
2019
Q4 | $66K | Buy |
873
+146
| +20% | +$6.39K | ﹤0.01% | 2720 |
|
|
2019
Q3 | $12K | Buy |
+727
| New | +$14.1K | ﹤0.01% | 3247 |
|
Other funds holding KRTX
Legal & General Group's KRTX Position: Q1 2024 in Review
Legal & General Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 32,839 shares — an estimated $10.4M sold.
Legal & General Group first reported a position in KRTX in Q3 2019 and held it in 18 quarters. The position peaked at $10.4M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- Legal & General Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Legal & General Group sold 32,839 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $10.4M.
- Legal & General Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
- Legal & General Group's Karuna Therapeutics, Inc. Common Stock position peaked at $10.4M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Legal & General Group's 13F filing for Q1 2024, filed 14 May 2024.